CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Acorda Therapeutics, Inc. - ACOR CFD

    10.4597
    0.97%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.4506
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Acorda Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 10.3597
    Open* 9.7997
    1-Year Change* 1546.18%
    Day's Range* 9.7997 - 10.4697
    52 wk Range 8.98-24.20
    Average Volume (10 days) 2,500.00
    Average Volume (3 months) 157.91K
    Market Cap 12.17M
    P/E Ratio -100.00K
    Shares Outstanding 1.24M
    Revenue 111.12M
    EPS -12.83
    Dividend (Yield %) N/A
    Beta 1.39
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 4, 2023 10.3597 0.5900 6.04% 9.7697 10.6397 9.7697
    Dec 1, 2023 10.1597 0.4000 4.10% 9.7597 10.1697 9.7097
    Nov 30, 2023 9.9597 0.2500 2.57% 9.7097 10.0597 9.7097
    Nov 29, 2023 9.9597 0.3000 3.11% 9.6597 9.9597 9.5997
    Nov 28, 2023 9.9997 -0.0400 -0.40% 10.0397 10.4297 9.5997
    Nov 27, 2023 9.6597 0.1000 1.05% 9.5597 9.9597 9.5097
    Nov 24, 2023 9.7297 0.2200 2.31% 9.5097 9.7297 9.5097
    Nov 22, 2023 9.5697 0.0100 0.10% 9.5597 9.5697 9.5597
    Nov 21, 2023 9.5997 0.0400 0.42% 9.5597 9.6597 9.5097
    Nov 20, 2023 9.5597 -0.0400 -0.42% 9.5997 9.8097 9.5097
    Nov 17, 2023 9.6597 0.0600 0.63% 9.5997 10.0597 9.5897
    Nov 16, 2023 9.5897 0.0000 0.00% 9.5897 10.0497 9.5897
    Nov 15, 2023 9.9697 0.3800 3.96% 9.5897 10.3597 9.5897
    Nov 14, 2023 9.8697 0.3400 3.57% 9.5297 10.8597 9.5297
    Nov 13, 2023 9.8497 0.3200 3.36% 9.5297 9.8597 9.5297
    Nov 10, 2023 9.5297 0.0700 0.74% 9.4597 9.7597 9.4597
    Nov 9, 2023 9.5097 0.0500 0.53% 9.4597 9.9397 9.4597
    Nov 8, 2023 9.5797 -0.2700 -2.74% 9.8497 9.8997 9.4597
    Nov 7, 2023 9.9797 0.3500 3.63% 9.6297 10.1697 9.6297
    Nov 6, 2023 9.6597 0.1700 1.79% 9.4897 9.6597 9.4897

    Acorda Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Acorda Therapeutics Inc Earnings Release
    Q4 2023 Acorda Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 118.566 129.071 152.967 192.408 471.433
    Revenue 118.566 129.071 152.967 192.408 471.433
    Cost of Revenue, Total 30.332 40.787 33.513 34.849 99.31
    Gross Profit 88.234 88.284 119.454 157.559 372.123
    Total Operating Expense 126.764 208.109 231.043 448.967 432.947
    Selling/General/Admin. Expenses, Total 105.956 118.999 152.576 192.846 172.254
    Research & Development 0.075 0.694 1.745 2.812 5.56
    Other Operating Expenses, Total -13.521 10.865 -49.581 -29.664 155.823
    Operating Income -8.198 -79.038 -78.076 -256.559 38.486
    Interest Income (Expense), Net Non-Operating -28.299 -30.03 -29.758 -17.702 -18.079
    Other, Net 1.25 -0.006 0.167 0.013 0.016
    Net Income Before Taxes -35.247 -109.074 -107.667 -274.248 20.423
    Net Income After Taxes -65.916 -103.954 -99.594 -272.966 18.882
    Minority Interest 0
    Net Income Before Extra. Items -65.916 -103.954 -99.594 -272.966 18.882
    Net Income -65.916 -103.954 -99.594 -272.966 33.682
    Income Available to Common Excl. Extra. Items -65.916 -103.954 -99.594 -272.966 18.882
    Income Available to Common Incl. Extra. Items -65.916 -103.954 -99.594 -272.966 33.682
    Diluted Net Income -65.916 -103.954 -99.594 -272.966 33.682
    Diluted Weighted Average Shares 0.98535 0.53105 0.4042 0.39593 0.39451
    Diluted EPS Excluding Extraordinary Items -66.896 -195.752 -246.398 -689.424 47.8621
    Diluted Normalized EPS -84.6027 -188.408 -146.651 -324.168 47.8621
    Unusual Expense (Income) -26.842 6 62.027 222.488 0
    Total Extraordinary Items 14.8
    Depreciation / Amortization 30.764 30.764 30.763 25.636
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 29.675 22.258 31.47 33.511 31.051
    Revenue 29.675 22.258 31.47 33.511 31.051
    Cost of Revenue, Total 3.065 3.234 4.56 11.005 8.8
    Gross Profit 26.61 19.024 26.91 22.506 22.251
    Total Operating Expense 33.307 33.734 4.061 38.5 44.966
    Selling/General/Admin. Expenses, Total 21.825 22.514 26.254 22.997 29.967
    Research & Development 0.004 0.001 0.009 0.014 0.025
    Depreciation / Amortization 7.691 7.691 7.691 7.691 7.691
    Unusual Expense (Income) -27.142 0 0.1
    Other Operating Expenses, Total 0.722 0.294 -7.311 -3.207 -1.617
    Operating Income -3.632 -11.476 27.409 -4.989 -13.915
    Interest Income (Expense), Net Non-Operating -7.715 -7.478 -5.835 -7.449 -7.454
    Other, Net 0.001 0.092 0 0 1.25
    Net Income Before Taxes -11.346 -18.862 21.574 -12.438 -20.119
    Net Income After Taxes -9.381 -16.824 19.142 -13.854 -46.682
    Net Income Before Extra. Items -9.381 -16.824 19.142 -13.854 -46.682
    Net Income -9.381 -16.824 19.142 -13.854 -46.682
    Income Available to Common Excl. Extra. Items -9.381 -16.824 19.142 -13.854 -46.682
    Income Available to Common Incl. Extra. Items -9.381 -16.824 19.142 -13.854 -46.682
    Diluted Net Income -9.381 -16.824 19.142 -13.854 -46.682
    Diluted Weighted Average Shares 1.242 1.2169 1.2192 1.2145 0.83915
    Diluted EPS Excluding Extraordinary Items -7.55314 -13.8253 15.7005 -11.4072 -55.6301
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -7.55314 -13.8253 1.23007 -11.4072 -55.5526
    Gain (Loss) on Sale of Assets
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 82.115 102.157 221.335 201.113 528.107
    Cash and Short Term Investments 37.536 45.634 71.369 125.839 445.553
    Cash & Equivalents 37.536 45.634 71.369 62.085 293.564
    Short Term Investments 0 63.754 151.989
    Total Receivables, Net 13.866 17.002 20.193 22.083 23.43
    Accounts Receivable - Trade, Net 13.866 17.002 20.193 22.083 23.43
    Total Inventory 12.752 18.548 28.677 25.221 29.014
    Prepaid Expenses 4.312 6.574 14.807 11.574 19.384
    Other Current Assets, Total 13.649 14.399 86.289 16.396 10.726
    Total Assets 395.595 455.47 632.68 799.718 1299.67
    Property/Plant/Equipment, Total - Net 7.89 11.133 25.744 165.977 60.519
    Property/Plant/Equipment, Total - Gross 14.645 46.13 61.768 230.453 117.426
    Accumulated Depreciation, Total -6.755 -34.997 -36.024 -64.476 -56.907
    Goodwill, Net 0 282.059
    Intangibles, Net 305.087 335.98 366.981 402.329 428.57
    Other Long Term Assets, Total 0.503 6.2 18.62 30.299 0.411
    Total Current Liabilities 37.95 54.025 137.252 86.385 140.256
    Accounts Payable 9.809 10.845 12.155 26.257 48.859
    Accrued Expenses 24.192 35.043 43.247 43.538 70.269
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 68.631 0.603 0.616
    Other Current Liabilities, Total 3.949 8.137 13.219 15.987 20.512
    Total Liabilities 301.973 304.333 394.725 488.898 687.683
    Total Long Term Debt 167.031 178.67 166.174 218.269 343.14
    Long Term Debt 167.031 178.67 166.174 218.269 343.14
    Deferred Income Tax 44.202 13.93 19.116 9.581 7.483
    Other Liabilities, Total 52.79 57.708 72.183 174.663 196.804
    Total Equity 93.622 151.137 237.955 310.82 611.983
    Common Stock 0.024 0.013 0.009 0.048 0.048
    Additional Paid-In Capital 1029.88 1023.14 1007.79 979.388 1005.1
    Retained Earnings (Accumulated Deficit) -936.273 -870.357 -766.403 -666.809 -393.843
    Treasury Stock - Common -0.638 -0.638 -0.638 -0.638 -2.133
    Other Equity, Total 0.628 -1.017 -2.803 -1.169 2.806
    Total Liabilities & Shareholders’ Equity 395.595 455.47 632.68 799.718 1299.67
    Total Common Shares Outstanding 1.21688 0.66221 0.4735 0.39752 0.39518
    Redeemable Preferred Stock 0
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 73.728 64.914 68.094 82.115 71.692
    Cash and Short Term Investments 32.468 25.27 30.255 37.536 20.696
    Cash & Equivalents 32.468 25.27 30.255 37.536 20.696
    Total Receivables, Net 11.977 13.39 9.19 13.866 14.69
    Accounts Receivable - Trade, Net 11.977 13.39 9.19 13.866 14.69
    Total Inventory 17.942 14.797 13.465 12.752 15.252
    Prepaid Expenses 5.042 5.48 4.125 4.312 5.111
    Other Current Assets, Total 6.299 5.977 11.059 13.649 15.943
    Total Assets 366.344 364.696 374.906 395.595 393.339
    Property/Plant/Equipment, Total - Net 6.706 6.928 7.412 7.89 8.366
    Intangibles, Net 282.006 289.7 297.393 305.087 312.779
    Other Long Term Assets, Total 3.904 3.154 2.007 0.503 0.502
    Total Current Liabilities 46.294 30.386 34.739 37.95 42.023
    Accounts Payable 12.33 3.175 2.854 9.809 11.505
    Accrued Expenses 30.922 23.389 28.573 25.225 28.159
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 3.042 3.822 3.312 2.916 2.359
    Total Liabilities 307.387 296.828 297.946 301.973 317.573
    Total Long Term Debt 181.043 176.164 171.496 167.031 187.689
    Long Term Debt 181.043 176.164 171.496 167.031 187.689
    Deferred Income Tax 38.544 39.556 41.805 44.202 42.228
    Other Liabilities, Total 41.506 50.722 49.906 52.79 45.633
    Total Equity 58.957 67.868 76.96 93.622 75.766
    Common Stock 0.001 0.001 0.024 0.024 0.024
    Additional Paid-In Capital 1030.24 1030.1 1029.95 1029.88 1029.7
    Retained Earnings (Accumulated Deficit) -971.366 -962.478 -953.097 -936.273 -955.415
    Treasury Stock - Common -0.638 -0.638 -0.638 -0.638 -0.638
    Other Equity, Total 0.717 0.88 0.719 0.628 2.09
    Total Liabilities & Shareholders’ Equity 366.344 364.696 374.906 395.595 393.339
    Total Common Shares Outstanding 1.2421 1.2421 1.21688 1.21688 1.21663
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -65.916 -103.954 -99.594 -272.966 33.682
    Cash From Operating Activities -20.924 -41.348 -61.006 -128.167 150.793
    Cash From Operating Activities 32.809 33.953 41.298 34.573 11.479
    Non-Cash Items 10.485 3.718 9.244 151.631 58.024
    Cash Taxes Paid 0.199 0.05 0.251 2.791 20.709
    Cash Interest Paid 7.157 0.006 6.67 6.056 6.064
    Changes in Working Capital 1.698 24.935 -11.954 -41.405 47.608
    Cash From Investing Activities -0.136 73.778 59.36 -0.505 -176.865
    Capital Expenditures -0.136 -0.191 -4.39 -90.426 -33.915
    Other Investing Cash Flow Items, Total 0 73.969 63.75 89.921 -142.95
    Cash From Financing Activities 0 -69.655 -1.668 -60.55 12.797
    Financing Cash Flow Items 0 -1.071 -4.67
    Issuance (Retirement) of Stock, Net -0.067 13.454
    Foreign Exchange Effects 0.512 -0.447 1.018 0.062 -0.412
    Net Change in Cash -20.548 -37.672 -2.296 -189.16 -13.687
    Issuance (Retirement) of Debt, Net 0 -69.655 -0.597 -55.813 -0.657
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -16.824 -65.916 -85.058 -71.205 -24.522
    Cash From Operating Activities -7.018 -20.924 -29.991 -28.151 -13.637
    Cash From Operating Activities 7.913 32.809 24.77 16.976 8.534
    Non-Cash Items 1.407 10.485 26.468 25.186 -1.122
    Cash Taxes Paid 0.006 0.199 0.133 0.133 0.005
    Cash Interest Paid 0 7.157 0.947 0.947 0
    Changes in Working Capital 0.486 1.698 3.829 0.892 3.473
    Cash From Investing Activities 0 -0.136 -0.259 -0.109 -0.039
    Capital Expenditures 0 -0.136 -0.259 -0.109 -0.039
    Other Investing Cash Flow Items, Total 0
    Cash From Financing Activities 0 0 0 0 0
    Financing Cash Flow Items 0 0 0
    Issuance (Retirement) of Debt, Net 0 0 0 0 0
    Foreign Exchange Effects 0.097 0.512 -0.79 -0.468 -0.092
    Net Change in Cash -6.921 -20.548 -31.04 -28.728 -13.768
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Davidson Kempner Capital Management LP Hedge Fund 4.4397 55145 1 2023-06-30 HIGH
    Renaissance Technologies LLC Hedge Fund 3.6681 45561 1296 2023-06-30 HIGH
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 2.7479 34131 -1 2023-06-30 MED
    Cohen (Ron) Individual Investor 0.6029 7488 0 2023-04-24 LOW
    Telemetry Investments, L.L.C. Hedge Fund 0.5334 6625 6625 2022-12-31 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.5215 6478 4 2023-06-30 LOW
    Wells Fargo Securities, LLC Research Firm 0.2997 3723 1 2023-06-30 HIGH
    Deutsche Bank S.p.A. Investment Advisor 0.1369 1700 0 2023-06-30 LOW
    Morgan Stanley & Co. LLC Research Firm 0.1018 1264 793 2023-06-30 MED
    Sabella (Lauren M) Individual Investor 0.0432 536 1 2023-04-24 LOW
    Clem (Kerry M) Individual Investor 0.0406 504 0 2023-04-24 LOW
    RBC Capital Markets Wealth Management Research Firm 0.0403 500 500 2023-06-30 LOW
    Russell Investments Trust Company Investment Advisor 0.0242 300 0 2023-06-30 LOW
    Group One Trading, L.P. Research Firm 0.0164 204 -124 2023-06-30 HIGH
    BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.0131 163 0 2023-06-30 LOW
    Aperio Group, LLC Investment Advisor 0.0109 135 0 2023-06-30 LOW
    Panem (Sandra) Individual Investor 0.0019 24 0 2023-04-24 LOW
    RBC Dominion Securities, Inc. Investment Advisor 0.001 13 0 2023-06-30 LOW
    Morgan Stanley Smith Barney LLC Investment Advisor 0.0008 10 2 2023-06-30 LOW
    Wells Fargo Bank, N.A. Bank and Trust 0.0007 9 1 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Acorda Therapeutics, Inc. Company profile

    About Acorda Therapeutics Inc

    Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Acorda Therapeutics Inc revenues decreased 16% to $129.1M. Net loss increased 4% to $104M. Revenues reflect License revenue segment decrease from $15M to $0K, Ampyra segment decrease of 14% to $84.6M. Higher net loss reflects Change in fair value of derivative liabi decrease of 97% to $1.2M (income), Changes in fair value of acquired contin increase from $30.9M (income) to $2.9M (expense).

    Equity composition

    Common Stock $.001 Par, 12/12, 80M auth., 39,804,493 issd. Treasury stock 12,420 shs. at $328K Insiders own 0.24%. IPO: 2/06, 5.5M shs. @ $6.00 by Banc of America Securities LLC,Lazard Capital Markets, Piper Jaffray & SG Cowenn & Co. 6/07, 3.6M Common Stock issd thru privateplacement, by Bank of America & Deuschte Bank & 1.2M shs issd upon conversion.

    Industry: Bio Therapeutic Drugs

    Two Blue Hill Plaza
    PEARL RIVER
    NEW YORK 10965
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    72.26 Price
    -1.450% 1D Chg, %
    Long position overnight fee -0.0225%
    Short position overnight fee 0.0006%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Gold

    2,019.84 Price
    -0.470% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.63 Price
    -0.530% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    15,876.80 Price
    +0.340% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading